Compare Etsy Inc (ETSY) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Etsy Inc vs Sanofi SA — how do they compare? Etsy Inc trades at $76.71 (market cap $6.90B), while Sanofi SA trades at $40.07 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 13.8× Etsy Inc's market cap, and Sanofi SA pays a 6.01% dividend while Etsy Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Etsy Inc for 67 Days and Sanofi SA for 94 Days on average.
| ETSY | SNY | |
|---|---|---|
Market Cap | $6.90B | $95.18B |
Volume | 2,923,867 | 2,995,646 |
Sector | Consumer Cyclical | Health |
52-Week High | $87.03 | $52.34 |
52-Week Low | $44.05 | $39.51 |
Typical Hold Time | 67 Days | 94 Days |
Enterprise Value | $8.85B | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ETSY trades at $75.14, up 5.11% today, reflecting strong momentum. The stock shows a bullish technical outlook with consistent earnings beats and a 53.33% analyst buy rating. Recent news highlights AI integration to enhance personalization and renewed payment partnerships, supporting growth. Revenue reached $2.88B in 2025, though net income margin dipped to 5.65%. Cash flow improved with $593.18M net inflow in 2025, but high debt and negative equity pose financial risks.
The outlook is cautiously optimistic with a consensus price target of $85.94 offering ~14% upside. Strengths include robust gross margins and strategic AI initiatives, but risks involve elevated valuation multiples, competitive pressures, and sensitivity to consumer spending trends. Investors should weigh growth potential against balance sheet concerns.
Sanofi (SNY) trades at $40.23, showing minimal daily movement with a 0.07% gain. The stock presents mixed signals with bearish technical indicators but strong fundamental performance, including three consecutive quarterly earnings beats. Recent expansion of the immunology alliance with Regeneron through an $8 billion deal highlights strategic growth initiatives. Valuation metrics show a P/E of 22.14 and P/S of 1.77, while profitability remains solid with a 72.77% gross margin.
SNY offers steady growth potential driven by pipeline expansion and Dupixent momentum, though patent expiration risks loom. Analyst sentiment is cautiously optimistic with 44% buy ratings, but technical weakness and projected 2026 earnings decline present near-term headwinds. The stock represents a balanced opportunity for long-term investors seeking pharmaceutical exposure with manageable risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Etsy Inc
Etsy operates a top-10 e-commerce marketplace operator in the U.S. and the U.K., with sizable operations in Germany, France, Australia, and Canada. The firm dominates an interesting niche, connecting buyers and sellers through its online market to exchange vintage and craft goods. With $13.5 billion in 2021 consolidated gross merchandise volume, the firm has cemented itself as one of the largest players in a quickly growing space, generating revenue from listing fees, commissions on sold items, advertising services, payment processing, and shipping labels. As of the end of 2021, the firm connected more than 96 million buyers and more than 7.5 million sellers on its marketplace properties: Etsy, Reverb (musical equipment), Elo7 (crafts in Brazil), and Depop (clothing resale).
Read more on ETSY →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
